Can TED Be Cured? What Remission Really Means

Thyroid eye disease (TED) can be driven into remission, often for years or even decades, but calling it “cured” overstates what current medicine delivers. The autoimmune process that causes TED leaves a lasting vulnerability, and the disease follows a natural arc of inflammation, plateau, and eventual quieting that doctors have tracked since the 1940s. Treatments have gotten dramatically better at controlling symptoms and reducing damage, yet the underlying immune misfiring can, in rare cases, reignite long after a patient thought the worst was behind them.

How TED Runs Its Course

TED follows a pattern often called Rundle’s curve, named after the ophthalmologist who first described it. The disease typically starts with an active inflammatory phase lasting one to three years, during which the tissues behind and around the eyes swell, the eyes may bulge forward, and eye movement can become restricted. After that peak, the inflammation gradually burns out on its own, even without treatment. A study tracking patients with mild, untreated Graves’ eye disease confirmed that clinical activity scores and severity measures dropped significantly over time, following a trajectory consistent with Rundle’s curve.¹

The catch is that once the inflammation subsides, not all the changes reverse. Swollen muscles and fat pads behind the eye can be replaced by scar tissue. Eyelid retraction may persist. Proptosis (the forward bulging of the eye) often improves partially but rarely returns to baseline on its own. So the disease “burns out,” but the person may be left with permanent changes that affect appearance, comfort, and sometimes vision. This is the gap between remission and cure: the fire goes out, but the damage it caused doesn’t always heal.

What Drives the Disease at a Molecular Level

Understanding why TED isn’t easily curable requires a look at what goes wrong in the first place. The core problem is an autoimmune attack. Antibodies that normally target the thyroid gland’s TSH receptor also happen to activate cells called orbital fibroblasts, the connective tissue cells behind the eyes. When these fibroblasts get switched on, they produce excess fat, fluid, and structural proteins that cause the swelling and tissue expansion characteristic of TED.

Recent research has clarified that the TSH receptor doesn’t act alone. It physically interacts with another receptor, the IGF-1 receptor, on the surface of orbital fibroblasts. Modeling and lab experiments have shown that the two receptors form a direct physical complex through their outer domains, which amplifies the inflammatory signal.² Stimulating antibodies that latch onto the TSH receptor can trigger signaling through the IGF-1 receptor as well, essentially hijacking two pathways at once.³

This dual-receptor mechanism matters for the “cure” question because it means the disease isn’t driven by a single antibody doing one thing. It’s a cascading crosstalk between receptors, antibodies, and inflammatory pathways. Eliminating the antibodies brings the disease under control, but the receptors remain, and the immune system retains the memory to produce those antibodies again. That’s fundamentally different from, say, treating a bacterial infection with an antibiotic and being done with it.

What Remission Actually Looks Like

Doctors define remission in TED primarily by the Clinical Activity Score, or CAS, a checklist of inflammatory signs like pain, redness, swelling, and worsening eye function. A CAS of 0 or 1 out of 7 means the disease is inactive. Remission means those inflammatory markers stay low over time, and the patient isn’t experiencing ongoing deterioration.

But remission doesn’t mean everything goes back to how it was before TED started. A person in remission might still have some degree of proptosis, eyelid changes, or residual double vision from scarred eye muscles. These are the “footprints” of the disease. Some people in remission have no noticeable residual effects; others have cosmetic or functional changes that bother them enough to pursue surgery. The disease isn’t progressing anymore, but the results of its earlier progression can persist.

This distinction matters because patients often hear “your disease is inactive” and interpret it as “you’re cured.” If they still have bulging eyes or stiff eyelids, that can feel like a contradiction. In reality, inactivity means the immune-driven inflammation has stopped, which is the goal. Addressing the leftover structural changes is a separate rehabilitation process.

Treatments That Push Toward Remission

The treatment landscape has changed substantially in recent years. For decades, the main tools were intravenous steroids to dampen inflammation and surgery to fix whatever damage remained after the disease burned out. That approach still forms the backbone of care for many patients.

Intravenous Steroids

High-dose intravenous methylprednisolone, typically given as a series of weekly infusions adding up to a cumulative dose of a few grams, remains a standard first-line treatment for moderate-to-severe active TED.⁴ Steroids tamp down the immune response quickly and can halt tissue damage during the active phase. The problem is that they don’t alter the underlying autoimmune process permanently. Once you stop the steroids, the disease can flare again if it hasn’t naturally wound down. Steroids also carry significant side effects at high doses, including weight gain, blood sugar spikes, and mood changes, which limits how long they can be used.

Teprotumumab

The real game-changer has been teprotumumab, a monoclonal antibody that blocks the IGF-1 receptor. By shutting down one half of the receptor crosstalk described above, teprotumumab reduces both the inflammation and the tissue expansion. In its pivotal trial, about 83% of patients treated with teprotumumab had a meaningful reduction in proptosis at 24 weeks, compared to 10% on placebo. Disease activity scores, double vision, and quality of life all improved significantly as well.⁵

A follow-up study showed that the benefits were durable for most patients. Among those who responded to teprotumumab, about 91% maintained their proptosis improvement and roughly 95% kept their low disease activity scores at nearly a year of follow-up after treatment ended.⁶ Those are impressive numbers, but the fact that retreatment data was also collected in the same study tells you something: some patients do relapse and need another course.

Other Biologics

For patients who don’t respond to steroids or teprotumumab, or who can’t access or tolerate them, other biologic drugs are being used. Rituximab, which depletes a type of immune cell involved in antibody production, and tocilizumab, which blocks an inflammatory signaling molecule, have shown promise in cases that resist standard treatment.⁷ These are typically second- or third-line options, used when the disease is aggressive or refractory.

Surgical Rehabilitation After Burnout

Once TED has been inactive for at least six months, surgery becomes an option for addressing what the disease left behind. Surgical rehabilitation follows a specific sequence: orbital decompression first (removing bone or fat behind the eye to reduce bulging), then eye muscle surgery to correct misalignment and double vision, then eyelid repositioning, and finally cosmetic refinement like blepharoplasty. Each step must be done in order because earlier procedures change the anatomy in ways that affect later ones.⁸

Not every patient needs all four stages. Someone with mild residual proptosis but good eye movement might only need decompression. Someone with persistent double vision might need muscle surgery. The point is that these operations are rehabilitative, not curative. They fix the structural aftermath, not the underlying autoimmune condition. But for many patients, surgery is what finally makes them feel like themselves again, which functionally achieves what “cure” means to most people asking this question.

The Risk of Late Relapse

One of the most unsettling aspects of TED is that it can come back, sometimes long after a patient thought the disease was permanently behind them. Late recurrence, defined as reactivation after at least five years of quiescence, is rare but documented. A recent case series described patients who relapsed 9, 20, 34, and even 40 years after their initial episode.⁹

These cases are exceptional, and most people with TED will never experience a late relapse. But they illustrate why “cure” is the wrong word. The autoimmune machinery doesn’t fully disarm. For most patients, the practical risk of reactivation is low enough to live normally, but the possibility never drops to zero. It’s more like a dormant volcano than a demolished building.

Smoking and Treatment Response

If there’s one modifiable factor that patients can directly control, it’s smoking. A systematic review found strong evidence that smoking is causally associated with both the development and progression of TED, with a clear dose-response relationship: heavier smokers had worse outcomes.¹⁰ Ex-smokers had a reduced risk compared to current smokers, which suggests that quitting can shift the odds even after the disease has started.

Smoking also blunts the effectiveness of treatment. A study directly comparing smokers and non-smokers receiving the same therapies for TED found that non-smokers had significantly faster and greater improvements in both disease activity scores and eye movement. The response to treatment was delayed and substantially poorer in smokers, and the effect was dose-dependent.¹¹ If you have TED and you smoke, quitting is arguably as important as any medication your doctor prescribes.

When the Thyroid Is Normal but the Eyes Are Not

A common misconception is that controlling thyroid hormone levels controls TED. The two conditions are related but not tightly coupled. A small but real proportion of patients develop eye disease while their thyroid function tests remain completely normal, a scenario called euthyroid Graves’ disease. A systematic review confirmed that this happens and that eye disease may even appear as the first sign of Graves’ disease, sometimes years before any thyroid abnormality shows up on bloodwork.¹²

The flip side is also worth noting. Patients who are euthyroid or hypothyroid at the time of TED presentation tend to develop less severe and less active disease, though their disease is more often asymmetric, which can make diagnosis trickier.¹³

The treatment of the thyroid itself also intersects with TED in a specific way. Antithyroid drugs and thyroidectomy don’t change TED’s natural course. Radioactive iodine, however, carries a small but documented risk of triggering new TED or worsening existing disease. When radioactive iodine treatment is chosen for a patient with mild TED, a short course of steroid prophylaxis is recommended, particularly if the eye disease is recent or risk factors for progression are present.¹⁴

When TED Threatens Vision

Most TED is uncomfortable and cosmetically distressing but does not endanger sight. The exception is dysthyroid optic neuropathy, where swollen eye muscles compress the optic nerve at the back of the orbit. This is a medical emergency. First-line treatment is high-dose intravenous steroids, and if the response is poor, urgent orbital decompression surgery is recommended to physically relieve pressure on the nerve.¹⁵ Endoscopic approaches through the nose can decompress the orbit when vision is acutely deteriorating and steroids aren’t working.¹⁶

Optic neuropathy is rare, but anyone with TED should know the warning signs: sudden loss of color vision, a dimming or graying out of the visual field, or rapidly worsening vision. These warrant same-day evaluation. The good news is that when caught and treated quickly, most patients recover useful vision. When caught late, the damage can be permanent.

The Psychological Weight of Chronic TED

Even after the active phase resolves, many patients struggle with the psychological burden of living with changed facial appearance. A study of patients with chronic TED in the United States found that those with low quality-of-life scores were far more likely to report pain, blurry vision, and double vision compared to patients with higher scores.¹⁷ The emotional impact of TED is frequently underestimated by clinicians who are focused on clinical activity scores and proptosis measurements.

Depression, social withdrawal, and anxiety about appearance are common even in patients whose disease is technically inactive. For some, the residual cosmetic changes are more distressing than the active disease ever was, because the active phase at least came with the hope that things would improve. Chronic stable disfigurement can feel more final. This is worth mentioning because “remission” in the medical sense doesn’t always line up with how the patient experiences their situation, and recognizing that gap is part of understanding what remission really means.

Tracking Disease Activity With Blood Markers

One practical question patients ask is how doctors know whether the disease is truly quiet or just simmering. Beyond the clinical exam, blood tests for thyroid-stimulating immunoglobulins (TSI) are increasingly used as a window into disease activity. Higher TSI levels track with higher disease activity and severity, and in patients with active TED, changes in TSI over time correlate with changes in clinical scores.¹⁸ Research has identified specific cutoff values for TSI that predict active disease with reasonable accuracy.¹⁹

These biomarkers aren’t perfect, and clinical judgment still matters. But falling TSI levels are a reassuring sign that the autoimmune drive behind TED is cooling off, and persistently elevated levels may prompt closer monitoring or more aggressive treatment. For patients in remission, periodically checking these levels can provide early warning if the disease starts stirring again.

What’s Coming in the Treatment Pipeline

A new class of drugs targeting the neonatal Fc receptor (FcRn) is entering clinical trials for TED. The idea is elegant: FcRn normally protects antibodies from being broken down, extending their lifespan in the body. By blocking FcRn, these drugs accelerate the destruction of all circulating antibodies, including the pathogenic ones that drive TED. Batoclimab, one such drug, reduced both total antibody levels and TED-specific antibody levels in an early trial, and several patients showed improvements in disease activity and proptosis.²⁰ A follow-up trial was terminated due to cholesterol elevations in treated patients, but larger phase 3 studies are now underway with both batoclimab and another FcRn blocker, efgartigimod, which is already approved for a different autoimmune condition.²¹

If these drugs prove effective and safe, they would offer a fundamentally different angle of attack from teprotumumab. Rather than blocking the receptor being activated, they’d reduce the levels of the antibodies doing the activating. In theory, combining both approaches could be more effective than either alone, though that remains to be tested. The broader implication is that the field is moving toward treatments that address the root autoimmune process more directly, which edges closer to the idea of a lasting remission even if it still doesn’t constitute a cure in the immunological sense. For patients diagnosed with TED today, the realistic expectation is effective control, meaningful cosmetic and functional restoration, and a disease that, for most, stays quiet once it settles down.